Acquisition builds on EVERSANA's commitment to investing in transformative, technology-first companies to modernize commercialization.

此次收购建立在EVERSANA对投资于变革性、技术优先公司以实现商业化现代化的承诺基础之上。

CHICAGO and LONDON

芝加哥和伦敦

,

，

Oct. 28, 2026

2026年10月28日

/PRNewswire/ --

/美通社/ --

EVERSANA®,

EVERSANA®，

a global provider of modern, AI-powered commercial services for the biopharmaceutical industry, today announced the acquisition of

一家为生物制药行业提供现代人工智能驱动商业服务的全球供应商，今日宣布收购

Estima Scientific

艾斯蒂玛科学

, an innovative, London-based health economics and outcomes research (HEOR) technology and services company.

，一家总部位于伦敦、专注于健康经济学与结果研究（HEOR）的创新型技术与服务公司。

Continue Reading

继续阅读

Estima Scientific has joined EVERSANA.

Estima Scientific 已加入 EVERSANA。

A leader in artificial intelligence (AI) and automation to accelerate elements of traditional HEOR processes, Estima Scientific will integrate its specialty consulting expertise and proprietary software into EVERSANA's market access and value & evidence solutions to help pharmaceutical companies demonstrate a drug's clinical and economic value more efficiently and transparently to payers.

作为人工智能（AI）和自动化领域的领军者，Estima Scientific 将加速传统卫生经济学与结果研究（HEOR）流程中的各个环节，并将其专业咨询专长及专有软件整合到 EVERSANA 的市场准入以及价值与证据解决方案中，以帮助制药公司更高效、更透明地向支付方证明药物的临床和经济价值。

Estima has developed a variety of web-based, generative-AI applications that integrate proprietary code, bringing efficiency and accuracy across economic modeling, systematic literature reviews (SLR), network meta-analysis (NMA), and more..

Estima 开发了多种基于网页的生成式人工智能应用程序，这些程序整合了专有代码，在经济建模、系统文献综述（SLR）、网络荟萃分析（NMA）等领域提升了效率与准确性。

Estima Scientific builds on EVERSANA's continued commitment to AI-enabled, technology-first offerings to drive accelerated commercialization for customers. EVERSANA's AI Agency platform,

Estima Scientific 依托 EVERSANA 对人工智能赋能、技术优先产品的持续承诺，助力客户加速商业化进程。EVERSANA 的 AI Agency 平台，

launched in 2025

2025年推出

and

和

expanded in August 2026

2026年8月扩建

, serves as the foundation for expanding the company's AI solutions.

，为扩展公司的人工智能解决方案奠定了基础。

'Today more than ever, the pharmaceutical industry must embrace AI to transform commercialization,' said Mark Thierer, Chief Executive Officer, EVERSANA. 'As we scale to serve global clients, adding best-in-class companies that embrace a technology first mindset is critical to our success. The Estima Scientific team checks every box and will seamlessly fit into our organization.'.

“如今，制药行业比以往任何时候都更需要拥抱人工智能，以变革商业化模式。”EVERSANA首席执行官马克·蒂雷尔表示。“随着我们扩大规模以服务全球客户，吸纳那些秉持‘技术优先’理念的顶尖企业，对我们的成功至关重要。Estima Scientific团队完全符合我们的所有要求，并将无缝融入我们的组织。”

Estima Scientific's team, including its co-founders Tim Reason and Andy Gimblett, will join EVERSANA's global workforce, ensuring continuity for existing clients while bringing expanded capabilities across EVERSANA. The company's solutions have been validated by large, top-tier pharmaceutical customers and leading health technology assessment (HTA) bodies, including the National Institute for Health and Care Excellence (NICE) in the United Kingdom..

Estima Scientific 的团队，包括其联合创始人 Tim Reason 和 Andy Gimblett，将加入 EVERSANA 的全球员工队伍，在确保为现有客户提供服务连续性的同时，为 EVERSANA 带来更广泛的能力。该公司的解决方案已获得大型顶级制药客户以及领先的健康技术评估（HTA）机构（包括英国国家健康与临床卓越研究所（NICE））的验证。

'Joining EVERSANA is an incredible milestone for Estima Scientific and a validation of the specialized technology and consulting expertise our team has built,' said Tim Reason, co-founder of Estima Scientific. 'The company's global scale and end-to-end commercial infrastructure will allow us to accelerate how pharmaceutical companies build and communicate evidence-based value to payers, helping patients gain faster access to life-changing therapies.'.

“加入EVERSANA是Estima Scientific的一个令人难以置信的里程碑，也是对我们团队所建立的专业技术和咨询专长的认可。”Estima Scientific联合创始人Tim Reason表示。“该公司的全球规模和端到端商业基础设施将使我们能够加速制药公司向支付方构建和传播基于证据的价值主张，帮助患者更快地获得改变生命的治疗方案。”

Estima was founded in 2019 by Tim Reason and Andy Gimblett, following long careers in HEOR and software development. The company has built a strong base of global clients that rely on its proprietary AI-powered technology to support research studies for leading global pharmaceutical brands.

Estima 由 Tim Reason 和 Andy Gimblett 于 2019 年创立，二人在卫生经济与结果研究（HEOR）及软件开发领域拥有深厚的职业积淀。公司已建立起庞大的全球客户基础，这些客户依赖其专有的 AI 驱动技术，为领先全球制药品牌的研究项目提供支持。

Financial details of the acquisition are not disclosed. Bourne Partners acted as exclusive financial adviser to Estima Scientific, and Wedlake Bell acted as legal adviser.

此次收购的财务细节未予披露。Bourne Partners 担任 Estima Scientific 的独家财务顾问，Wedlake Bell 担任法律顾问。

About EVERSANA®

关于 EVERSANA®

EVERSANA® is an independent provider of modern commercialization services to the biopharmaceutical industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers.

EVERSANA® 是一家面向生物制药行业的独立现代商业化服务提供商。公司的综合解决方案以患者体验为核心，覆盖产品生命周期的各个阶段，旨在为患者、处方医生、渠道合作伙伴和支付方创造长期、可持续的价值。

The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit .

该公司为650多家机构提供服务，包括创新型初创企业和成熟制药公司，旨在推动生命科学解决方案，共创更健康的世界。如需了解更多关于EVERSANA的信息，请访问。

eversana.com

eversana.com

or connect through

或通过以下方式连接

LinkedIn

领英

and

和

X

X

.

。

About Estima Scientific

关于艾斯提玛科学

Estima Scientific is a London-based health economics and outcomes research (HEOR) technology and services company. By combining specialist consulting with proprietary, AI-powered software, Estima Scientific helps pharmaceutical and biotechnology companies demonstrate therapeutic value to global payers and health technology assessment bodies efficiently.

Estima Scientific 是一家总部位于伦敦的卫生经济学与结果研究（HEOR）技术及服务公司。通过将专业咨询与专有的人工智能驱动软件相结合，Estima Scientific 帮助制药和生物技术公司高效地向全球支付方和卫生技术评估机构证明其治疗价值。

To learn more, visit .

欲了解更多信息，请访问。

estima-sci.com.

estima-sci.com

Media Contact

媒体联系人

Matt Braun

马特·布劳恩

Vice President, Corporate Communications

企业传播副总裁

[email protected]

[email protected]

SOURCE EVERSANA

来源：EVERSANA